Jun 29, 2026
A living insulin implant from Technion researchers achieved one year of steady blood sugar control in diabetic mice, while millions worldwide still lack access to insulin medication. Animal trials showed beta cells could auto-dose insulin, though immune barriers remain before human trials. Meanwhile, only about half of type 2 diabetes patients globally have access to needed insulin, with the problem affecting both low- and high-income countries.
May 13, 2026
Microgravity drug research is expanding from ISS crystal studies to commercial manufacturing efforts. New experiments and a Varda-United Therapeutics collaboration target improved drug stability, delivery and production.
May 04, 2026
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
May 02, 2026
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
Apr 22, 2026
Diabetes and heart disease can impair sexual function by damaging blood vessels, nerves and circulation. Sexual dysfunction may also be an early warning sign of underlying vascular damage.
Apr 20, 2026
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
Apr 07, 2026
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
Mar 26, 2026
New research reveals metformin regulates blood sugar through brain pathways involving the Rap1 protein in the hypothalamus. The study shows suppressing Rap1 in the brain prevents metformin from lowering blood sugar in diabetic mice. These findings could lead to new diabetes treatments targeting this brain pathway.
Mar 19, 2026
Analysis shows around a third of 54 drugs on TrumpRx.gov are cheaper in the UK, while the platform offers significant savings primarily for obesity and fertility drugs not typically covered by insurance.
Mar 18, 2026
New research shows home-based exercise reduces cognitive impairment during chemotherapy, while cardio-oncology programs monitor and minimize heart complications from cancer treatments that pose cardiovascular risks to survivors.
Mar 14, 2026
Eli Lilly's orforglipron demonstrated superior A1C reduction and weight loss compared to oral semaglutide in the ACHIEVE-3 trial, with regulatory submissions filed in over 40 countries and a potential US decision expected in Q2 2026.
Mar 12, 2026
The global precision medicine market reached $82.1 billion in 2025 and is expected to grow to $179.4 billion by 2034. Researchers emphasize that precision nutrition interventions must demonstrate cost-effectiveness to deliver patient benefits.
Feb 28, 2026
Oral semaglutide reduced heart failure events by 22% in Type 2 diabetes patients with existing heart failure in a trial of nearly 9,650 adults, with particular benefit in HFpEF cases.
Feb 26, 2026
New analysis suggests leptin hormone could normalize blood sugar in type 1 diabetes by acting on the brain, potentially offering an alternative to daily insulin injections based on research dating back to 2011.
Feb 26, 2026
Recent research shows younger heart disease patients face unique parenting challenges, middle-aged healthy eating protects against cognitive decline, and timing evening meals three hours before bed improves cardiovascular markers.
Feb 17, 2026
Novo Nordisk sues telehealth companies over compounded weight-loss drugs as employers explore AI-based alternatives to costly GLP-1 medications. About 1 in 8 Americans now take GLP-1 drugs for weight loss or diabetes.
Feb 20, 2026
Researchers discovered that red blood cells act as "glucose sponges" in low-oxygen conditions, dramatically lowering blood sugar levels. A new drug called HypoxyStat completely reversed high blood sugar in diabetic mice, working better than existing medications.
Feb 17, 2026
Novo Nordisk's investigational dual agonist CagriSema demonstrated superior efficacy to Ozempic in a phase 3 trial for type 2 diabetes patients, while the company faces market share losses to Eli Lilly in the GLP-1 space.
Feb 15, 2026
The FDA will consider revoking safety exemptions for ultra-processed foods including corn syrup, while retatrutide, a triple-receptor weight loss drug, advances through phase three clinical trials without yet receiving regulatory approval.
Feb 13, 2026
New research shows semaglutide cuts cardiovascular event risk by 4% per 5kg weight loss, with two-thirds of heart benefits unexplained by weight reduction alone. Study of 17,604 participants suggests multiple protective mechanisms beyond weight loss.
